Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation
- Status
- COMPLETED
- Phase
- N/A
Clinical Trials Related to Myelodysplastic Syndromes
Related studies linked through entity extraction aliases.
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder
- Status
- COMPLETED
- Phase
- PHASE2
Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes
- Status
- COMPLETED
- Phase
- PHASE2
Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Bortezomib in Treating Patients With Myelodysplastic Syndromes
- Status
- COMPLETED
- Phase
- PHASE2
Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer
- Status
- TERMINATED
- Phase
- NA
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
- Status
- COMPLETED
- Phase
- PHASE2
G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
- Status
- TERMINATED
- Phase
- NA
Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS)
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
- Status
- TERMINATED
- Phase
- PHASE1
A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE2
Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes
- Status
- COMPLETED
- Phase
- PHASE2
Transfusion Effects in Myelodysplastic Patients: Limiting Exposure
- Status
- WITHDRAWN
- Phase
- PHASE4